1. hospitalized but no longer requires ongoing inpatient care (i.e., discharge is anticipated in ≤24 hours) 2. patient is not anticipated to survive \>48 hours or is under palliative care 3. evidence of critical illness, defined by at least 1 of the following: * respiratory failure requiring at least 1 of the following: 1. endotracheal intubation and mechanical ventilation, oxygen delivered by high flow nasal cannula 2. noninvasive positive pressure ventilation (nipvv), or 3. extracorporeal membrane oxygenation (ecmo) or clinical diagnosis of respiratory failure * shock (defined by systolic blood pressure (bp) \<90 mm hg, or diastolic blood pressure (bp) \<60 mm hg or requiring vasopressors), or * multi-organ dysfunction/failure 4. severe central nervous system (cns) conditions 5. chronic kidney disease requiring dialysis 6. known allergy to the study drug or salicylate containing medications. 7. suspected and/or confirmed pregnancy or breastfeeding 8. current or planned participation in any other clinical trial of a treatment being developed under a us investigational new drug (ind) or emergency use authorization (eua). 9. patients receiving chemotherapeutic agents and/or immunomodulators (including monoclonal antibodies (mabs) or plasma transfusions) for chronic disease conditions.

1. hospitalized but no longer requires ongoing inpatient care (i.e., discharge is anticipated in ≤24 hours) 2. patient is not anticipated to survive \>48 hours or is under palliative care 3. evidence of critical illness, defined by at least 1 of the following: * respiratory failure requiring at least 1 of the following: 1. endotracheal intubation and mechanical ventilation, oxygen delivered by high flow nasal cannula 2. noninvasive positive pressure ventilation (nipvv), or 3. extracorporeal membrane oxygenation (ecmo) or clinical diagnosis of respiratory failure * shock (defined by systolic blood pressure (bp) \<90 mm hg, or diastolic blood pressure (bp) \<60 mm hg or requiring vasopressors), or * multi-organ dysfunction/failure 4. severe central nervous system (cns) conditions 5. chronic kidney disease requiring dialysis 6. known allergy to the study drug or salicylate containing medications. 7. suspected and/or confirmed pregnancy or breastfeeding 8. current or planned participation in any other clinical trial of a treatment being developed under a us investigational new drug (ind) or emergency use authorization (eua). 9. patients receiving chemotherapeutic agents and/or immunomodulators (including monoclonal antibodies (mabs) or plasma transfusions) for chronic disease conditions.

hospitalized but no longer requires ongoing inpatient care (i.e., discharge is anticipated in ≤24 hours) patient is not anticipated to survive >48 hours or is under palliative care evidence of critical illness, defined by at least 1 of the following: respiratory failure requiring at least 1 of the following: endotracheal intubation and mechanical ventilation, oxygen delivered by high flow nasal cannula noninvasive positive pressure ventilation (nipvv), or extracorporeal membrane oxygenation (ecmo) or clinical diagnosis of respiratory failure shock (defined by systolic blood pressure (bp) <90 mm hg, or diastolic blood pressure (bp) <60 mm hg or requiring vasopressors), or multi-organ dysfunction/failure severe central nervous system (cns) conditions chronic kidney disease requiring dialysis known allergy to the study drug or salicylate containing medications. suspected and/or confirmed pregnancy or breastfeeding current or planned participation in any other clinical trial of a treatment being developed under a us investigational new drug (ind) or emergency use authorization (eua). patients receiving chemotherapeutic agents and/or immunomodulators (including monoclonal antibodies (mabs) or plasma transfusions) for chronic disease conditions.

hospitalized but no longer requires ongoing inpatient care (i.e., discharge is anticipated in ≤24 hours) patient is not anticipated to survive >48 hours or is under palliative care evidence of critical illness, defined by at least 1 of the following: respiratory failure requiring at least 1 of the following: endotracheal intubation and mechanical ventilation, oxygen delivered by high flow nasal cannula noninvasive positive pressure ventilation (nipvv), or extracorporeal membrane oxygenation (ecmo) or clinical diagnosis of respiratory failure shock (defined by systolic blood pressure (bp) <90 mm hg, or diastolic blood pressure (bp) <60 mm hg or requiring vasopressors), or multi-organ dysfunction/failure severe central nervous system (cns) conditions chronic kidney disease requiring dialysis known allergy to the study drug or salicylate containing medications. suspected and/or confirmed pregnancy or breastfeeding current or planned participation in any other clinical trial of a treatment being developed under a us investigational new drug (ind) or emergency use authorization (eua). patients receiving chemotherapeutic agents and/or immunomodulators (including monoclonal antibodies (mabs) or plasma transfusions) for chronic disease conditions.

1. hospitalized but no longer requires ongoing inpatient care (i.e., discharge is anticipated in ≤24 hours) 2. patient is not anticipated to survive >48 hours or is under palliative care 2. respiration rate ≥30 breaths per minute, heart rate ≥125 beats per minute, or oxygen saturation (spo2) ≤93% on ≤ 2 l/min nasal cannula oxygen 3. evidence of critical illness, defined by at least 1 of the following: ● respiratory failure requiring at least 1 of the following: endotracheal intubation and mechanical ventilation, oxygen delivered by high flow nasal cannula noninvasive positive pressure ventilation (nipvv), or extracorporeal membrane oxygenation (ecmo) or clinical diagnosis of respiratory failure shock (defined by systolic blood pressure (bp) <90 mm hg, or diastolic blood pressure (bp) <60 mm hg or requiring vasopressors), or multi-organ dysfunction/failure 4. severe central nervous system (cns) conditions 5. chronic kidney disease requiring dialysis 6. known allergy to the study drug or salicylate containing medications. 7. suspected and/or confirmed pregnancy or breastfeeding 8. current or planned participation in any other clinical trial of a treatment being developed under a us investigational new drug (ind) or emergency use authorization (eua). 9. patients receiving chemotherapeutic agents and/or immunomodulators (including monoclonal antibodies (mabs) or plasma transfusions) for chronic disease conditions. 10. patients who receive the severe acute respiratory syndrome coronavirus 2 vaccine

1. hospitalized but no longer requires ongoing inpatient care (i.e., discharge is anticipated in ≤24 hours) 2. patient is not anticipated to survive >48 hours or is under palliative care 2. respiration rate ≥30 breaths per minute, heart rate ≥125 beats per minute, or oxygen saturation (spo2) ≤93% on ≤ 2 l/min nasal cannula oxygen 3. evidence of critical illness, defined by at least 1 of the following: ● respiratory failure requiring at least 1 of the following: endotracheal intubation and mechanical ventilation, oxygen delivered by high flow nasal cannula noninvasive positive pressure ventilation (nipvv), or extracorporeal membrane oxygenation (ecmo) or clinical diagnosis of respiratory failure shock (defined by systolic blood pressure (bp) <90 mm hg, or diastolic blood pressure (bp) <60 mm hg or requiring vasopressors), or multi-organ dysfunction/failure 4. severe central nervous system (cns) conditions 5. chronic kidney disease requiring dialysis 6. known allergy to the study drug or salicylate containing medications. 7. suspected and/or confirmed pregnancy or breastfeeding 8. current or planned participation in any other clinical trial of a treatment being developed under a us investigational new drug (ind) or emergency use authorization (eua). 9. patients receiving chemotherapeutic agents and/or immunomodulators (including monoclonal antibodies (mabs) or plasma transfusions) for chronic disease conditions. 10. patients who receive the severe acute respiratory syndrome coronavirus 2 vaccine

1. hospitalized but no longer requires ongoing inpatient care (i.e., discharge is anticipated in ≤24 hours) 2. patient is not anticipated to survive >48 hours or is under palliative care 2. respiration rate ≥30 breaths per minute, heart rate ≥125 beats per minute, or oxygen saturation (spo2) ≤93% on ≤ 2 l/min nasal cannula oxygen 3. evidence of critical illness, defined by at least 1 of the following: ● respiratory failure requiring at least 1 of the following: 1. endotracheal intubation and mechanical ventilation, oxygen delivered by high flow nasal cannula 2. noninvasive positive pressure ventilation (nipvv), or 3. extracorporeal membrane oxygenation (ecmo) or clinical diagnosis of respiratory failure - shock (defined by systolic blood pressure (bp) <90 mm hg, or diastolic blood pressure (bp) <60 mm hg or requiring vasopressors), or - multi-organ dysfunction/failure 4. severe central nervous system (cns) conditions 5. chronic kidney disease requiring dialysis 6. known allergy to the study drug or salicylate containing medications. 7. suspected and/or confirmed pregnancy or breastfeeding 8. current or planned participation in any other clinical trial of a treatment being developed under a us investigational new drug (ind) or emergency use authorization (eua). 9. patients receiving chemotherapeutic agents and/or immunomodulators (including monoclonal antibodies (mabs) or plasma transfusions) for chronic disease conditions. 10. patients who receive the severe acute respiratory syndrome coronavirus 2 vaccine

1. hospitalized but no longer requires ongoing inpatient care (i.e., discharge is anticipated in ≤24 hours) 2. patient is not anticipated to survive >48 hours or is under palliative care 2. respiration rate ≥30 breaths per minute, heart rate ≥125 beats per minute, or oxygen saturation (spo2) ≤93% on ≤ 2 l/min nasal cannula oxygen 3. evidence of critical illness, defined by at least 1 of the following: ● respiratory failure requiring at least 1 of the following: 1. endotracheal intubation and mechanical ventilation, oxygen delivered by high flow nasal cannula 2. noninvasive positive pressure ventilation (nipvv), or 3. extracorporeal membrane oxygenation (ecmo) or clinical diagnosis of respiratory failure - shock (defined by systolic blood pressure (bp) <90 mm hg, or diastolic blood pressure (bp) <60 mm hg or requiring vasopressors), or - multi-organ dysfunction/failure 4. severe central nervous system (cns) conditions 5. chronic kidney disease requiring dialysis 6. known allergy to the study drug or salicylate containing medications. 7. suspected and/or confirmed pregnancy or breastfeeding 8. current or planned participation in any other clinical trial of a treatment being developed under a us investigational new drug (ind) or emergency use authorization (eua). 9. patients receiving chemotherapeutic agents and/or immunomodulators (including monoclonal antibodies (mabs) or plasma transfusions) for chronic disease conditions. 10. patients who receive the severe acute respiratory syndrome coronavirus 2 vaccine

1. hospital discharge is anticipated in ≤24 hours. 2. respiration rate ≥30 breaths per minute, heart rate ≥125 beats per minute, or oxygen saturation (spo2) ≤93% on ≤ 2 l/min nasal cannula oxygen 3. evidence of critical illness, defined by at least 1 of the following: - respiratory failure requiring at least 1 of the following: 1. endotracheal intubation and mechanical ventilation, oxygen delivered by high flow nasal cannula 2. noninvasive positive pressure ventilation (nipvv), or 3. extracorporeal membrane oxygenation (ecmo) or clinical diagnosis of respiratory failure - shock (defined by systolic blood pressure (bp) <90 mm hg, or diastolic blood pressure (bp) <60 mm hg or requiring vasopressors), or - multi-organ dysfunction/failure 4. severe central nervous system (cns) conditions, e.g., stroke 5. chronic kidney disease requiring dialysis 6. known allergy to the study drug or salicylate containing medications. 7. suspected and/or confirmed pregnancy or breastfeeding 8. current or planned participation in any other clinical trial of a treatment being developed under a us investigational new drug (ind) or emergency use authorization (eua). 9. patients receiving chemotherapeutic agents and/or immunomodulators (including monoclonal antibodies (mabs) or plasma transfusions) for chronic disease conditions.

1. hospital discharge is anticipated in ≤24 hours. 2. respiration rate ≥30 breaths per minute, heart rate ≥125 beats per minute, or oxygen saturation (spo2) ≤93% on ≤ 2 l/min nasal cannula oxygen 3. evidence of critical illness, defined by at least 1 of the following: - respiratory failure requiring at least 1 of the following: 1. endotracheal intubation and mechanical ventilation, oxygen delivered by high flow nasal cannula 2. noninvasive positive pressure ventilation (nipvv), or 3. extracorporeal membrane oxygenation (ecmo) or clinical diagnosis of respiratory failure - shock (defined by systolic blood pressure (bp) <90 mm hg, or diastolic blood pressure (bp) <60 mm hg or requiring vasopressors), or - multi-organ dysfunction/failure 4. severe central nervous system (cns) conditions, e.g., stroke 5. chronic kidney disease requiring dialysis 6. known allergy to the study drug or salicylate containing medications. 7. suspected and/or confirmed pregnancy or breastfeeding 8. current or planned participation in any other clinical trial of a treatment being developed under a us investigational new drug (ind) or emergency use authorization (eua). 9. patients receiving chemotherapeutic agents and/or immunomodulators (including monoclonal antibodies (mabs) or plasma transfusions) for chronic disease conditions.